Rentschler Biotechnologie and Boehringer Ingelheim, both companies in biopharmaceutical development and production, have signed a preferred partnership agreement
The cooperation will enable Rentschler Biotechnologie's clients to gain access to Boehringer Ingelheim's large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and vice versa, Boehringer Ingelheim's clients to use Rentschler's facilities of process development and intermediate-scale clinical supply production.
Through the cooperation clients from the pharmaceutical and the biotech industry will benefit from the combined development and manufacturing know-how and facilities, leading to increased flexibility and ultimately more customized services.
Compatible bioprocessing methods guarantee a seamless project transfer between the companies which are conveniently located in close vicinity.
Rentschler Biotechnologie, a full-service contract manufacturer focused on process development and small to medium scale production of mammalian cell-derived biopharmaceuticals, currently operates eight independent GMP lines with fermenter volumes of up to 500litres.
A 2500l has recently been qualified and is going to start operations.
Boehringer Ingelheim, who offers similar services with technologies optimised for large scale industrial production, runs one of the world's largest biotech facilities with fermenter volumes of up to 15,000l.
"The cooperation with Boehringer Ingelheim will increase the value of our services, as both companies will benefit from the combined expertise and the easy transfer from small/medium to large scale production" commented Dr Wieland W.
Wolf, vice chairman of Rentschler.
Rolf Werner, Corporate Senior VP Biopharmaceuticals, Boehringer Ingelheim said: "Rentschler Biotechnologie is a strong partner for process development and supply of clinical material in Europe and complements our worldwide strategic Production Alliance Network.
"Based on compatible process technologies and Boehringer Ingelheims proprietary know-how and expertise in high titer and high yield manufacturing process formats we will combine state-of-the-art development at Rentschler for accelerated time to clinic with a smooth technology transfer to Boehringer Ingelheim for large-scale commercial manufacturing".
